An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?The Motley Fool • 07/11/26
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett SyndromeZacks Investment Research • 06/29/26
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In FocusSeeking Alpha • 06/29/26
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?Zacks Investment Research • 06/29/26
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome TherapyBenzinga • 06/26/26
The Surprising Reversal That Drove Acadia Pharma Closer To A BreakoutInvestors Business Daily • 06/26/26
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/26
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE GrowthMarketBeat • 05/19/26
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data LoomsMarketBeat • 05/13/26
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthZacks Investment Research • 05/07/26
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/06/26
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial GuidanceBusiness Wire • 05/06/26
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.Business Wire • 04/30/26
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingBusiness Wire • 04/17/26
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Business Wire • 04/15/26
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/08/26